A new study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” shows the program is misused.
All Nations Must Respect and Protect Intellectual Property Rights
World Intellectual Property (IP) Day is a good time to remind all countries of the need to protect and respect IP rights.
CAGW Joins Coalition To Oppose Price Controls
CAGW joins 75 national and state-based organizations expressing their opposition to pharmaceutical price controls under the Most Favored Nations policy.
Bad Policies Are Being Proposed by HHS Secretary Nominee Xavier Becerra
The first clue that Joe Biden, the presumptive 46th President of the United States, was choosing someone he did not know well as his nominee for secretary of HHS was when he mispronounced his name and incorrectly named the agency he would direct.
The Fourth Circuit Was Right to Reject Price Controls for Generic Drugs
This prudent decision will send a strong message to other state legislatures across the country not to pursue similar legislation.
Vote NO on AB 215 – Pharmaceutical – Nevada
Nevada State Assembly 401 South Carson Street Carson City, Nevada 89701-4747 Dear Assembly Member, AB 215, a so-called pharmaceutical price transparency bill, was introduced on February 13, 2017 and is currently being considered by the Assembly Committee on Health and Human Services. It would require pharmaceutical companies to provide to the Division of Insurance an […]